Large normal alleles of ATXN2 decrease age at onset in transthyretin familial amyloid polyneuropathy Val30Met patients

• Published in: Annals of neurology 2019-02, Vol.85 (2), p.251-258
• Main Authors: Santos, Diana, Coelho, Teresa, Alves‐Ferreira, Miguel, Sequeiros, Jorge, Mendonça, Denisa, Alonso, Isabel, Sousa, Alda, Lemos, Carolina
• Format: Article
• Language: English
• Subjects: Adult; Age of Onset; Alleles; Amyloid; Amyloid Neuropathies, Familial - genetics; Asymptomatic Diseases; Ataxin-2 - genetics; Capillary electrophoresis; Confidence intervals; Electrophoresis; European Continental Ancestry Group - genetics; Female; Genes; Genes, Modifier; Humans; Male; Metabolism; Middle Aged; Mitochondria; Neurological diseases; Oligonucleotides; Patients; Polymerase chain reaction; Polyneuropathy; Portugal; Prealbumin - genetics; Primers; Prognosis; Ribonucleic acid; Risk analysis; Risk factors; RNA; Substitution reactions; Transthyretin; Trinucleotide Repeat Expansion - genetics; Young Adult
• ISSN: 0364-5134; 1531-8249
• DOI: 10.1002/ana.25409

Objective Transthyretin (TTR)‐related familial amyloid polyneuropathy (FAP) is an autosomal dominant neurological disease, caused most frequently by a Val30Met (now classified as Val50Met) substitution in TTR. Age at onset (AO) ranges from 19 to 82 years, and variability exists mostly between generations. Unstable oligonucleotide repeats in various genes are the mechanism behind several neurological diseases, found also to act as modifiers for other disorders. Our aim was to investigate whether large normal repeat alleles of 10 genes had a possible modifier effect in AO in Portuguese TTR‐FAP Val30Met families. Methods We analyzed 329 Portuguese patients from 123 families. Repeat length (at ATXN1, ATXN2, ATXN3, ATXN7, TBP, ATN1, HTT, JPH3, AR, and DMPK) was assessed by single and multiplex polymerase chain reaction, using fluorescently labeled primers, followed by capillary electrophoresis. We used a family‐centered approach, and generalized estimating equations were used to account for AO correlation between family members. Results For ATXN2, the presence of at least 1 allele longer than 22 CAGs was significantly associated with an earlier onset in TTR‐FAP Val30Met, decreasing mean AO by 6 years (95% confidence interval = −8.81 to −2.19, p = 0.001). No association was found for the remaining repeat loci. Interpretation Length of normal repeats at ATXN2 may modify AO in TTR‐FAP Val30Met and may function as a risk factor. This can be due to the role of ATXN2 in RNA metabolism and as a modulator of various cellular processes, including mitochondrial stress. This may have relevant implications for prognosis and the follow‐up of presymptomatic carriers. ANN NEUROL 2019;85:251–258.